Schräder R, Abel J, Sievert H, Friedmann A, Kaltenbach M, Kober G
Abteilung für Kardiologie, Johann Wolfgang Goethe-Universität, Frankfurt am Main.
Z Kardiol. 1989 Jan;78(1):33-40.
The nonionic-dimeric compound lotrolan (0.27 osmol/kg, 280 mg J/ml) is the first contrast medium with plasma-isotonic osmolality and sufficient iodine content for intravascular use. In 15 patients with coronary heart disease, the cardiac side effects of 1) lotrolan, 2) nonionic-monomeric lopromide (0.77 osmol/kg, 370 mg J/ml and 3) ionic-monomeric Amidotrizoate (2.1 osmol/kg, 370 mg J/ml) were compared intraindividually following randomized left coronary artery injections (8 ml). Electrocardiographic indices, aortic pressure, coronary sinus flow (thermodilution method), and coronary vascular resistance were determined before, during, and 60 s after each injection. Heart rate remained almost unchanged with lotrolan (+/- 3%) and lopromide (-8%). Amidotrizoate (-16%), however, caused a significant bradycardia. Aortic pressure decreased markedly after Amidotrizoate (-12%) but only moderately after lopromide (-7%) and lotrolan (-6%). Coronary sinus flow increased to the same extent with lopromide (+66%) and Amidotrizoate (+72%), but less with lotrolan (+43%). Coronary vascular resistance dropped significantly more following lopromide (-38%) and Amidotrizoate (-43%) than after lotrolan (-27%). As opposed to Amidotrizoate and lopromide, lotrolan caused only slight changes in heart rate, blood pressure, and coronary hemodynamics, presumably due to its plasma-isotonic osmolality. Only minor differences were found between the cardiac effects of Amidotrizoate and lopromide. The diagnostic quality of the angiograms, however, was better with Amidotrizoate and lopromide. Thus, due to its reduced cardiac side effects, lotrolan may only be useful in the case of experimental investigations applying digital techniques.
非离子二聚体化合物洛多洛尔(0.27 渗透压摩尔浓度/千克,280 毫克碘/毫升)是首个具有血浆等渗渗透压且碘含量足以用于血管内注射的造影剂。对 15 例冠心病患者进行随机左冠状动脉注射(8 毫升)后,对以下三种造影剂的心脏副作用进行个体内比较:1)洛多洛尔;2)非离子单体碘普罗胺(0.77 渗透压摩尔浓度/千克,370 毫克碘/毫升);3)离子单体泛影酸盐(2.1 渗透压摩尔浓度/千克,370 毫克碘/毫升)。在每次注射前、注射期间及注射后 60 秒测定心电图指标、主动脉压、冠状窦血流(热稀释法)和冠状血管阻力。使用洛多洛尔(±3%)和碘普罗胺(-8%)时心率几乎无变化。然而,泛影酸盐(-16%)导致显著心动过缓。泛影酸盐注射后主动脉压显著下降(-12%),而碘普罗胺(-7%)和洛多洛尔(-6%)注射后仅适度下降。碘普罗胺(+66%)和泛影酸盐(+72%)使冠状窦血流增加程度相同,但洛多洛尔(+43%)增加程度较小。碘普罗胺(-38%)和泛影酸盐(-43%)注射后冠状血管阻力下降幅度显著大于洛多洛尔(-27%)。与泛影酸盐和碘普罗胺不同,洛多洛尔对心率、血压和冠状血流动力学仅产生轻微变化,可能是由于其血浆等渗渗透压。泛影酸盐和碘普罗胺的心脏效应之间仅发现微小差异。然而,泛影酸盐和碘普罗胺造影的诊断质量更好。因此,由于其心脏副作用较小,洛多洛尔可能仅在应用数字技术的实验研究中有用。